Back to Search
Start Over
Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis
- Source :
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 20(1)
- Publication Year :
- 2019
-
Abstract
- Background Cystic fibrosis (CF) patients have reduced intestinal absorption of sterols and, despite enhanced endogenous synthesis, low plasma cholesterol. Lumacaftor/ivacaftor CFTR protein modulator therapy is used to improve the clinical outcome of CF patients homozygous for F508del mutation (homo-deltaF508). Aim of the study is to evaluate the cholesterol metabolism and hepatobiliary injury/function in adult homo-deltaF508 patients, before and after lumacaftor/ivacaftor treatment. Baseline parameters in homo-deltaF508 patients were compared to those in CF patients compound heterozygous for F508del mutation and another severe mutation (hetero-deltaF508). Methods Cholesterol metabolism was evaluated measuring plasma phytosterols and cholestanol, as intestinal absorption markers, and lathosterol, as liver biosynthesis marker. We quantified serum vitamin E, as nutritional marker. We evaluated liver injury by aspartate aminotransferase (AST) and alanine transaminase (ALT), biliary injury by γ-glutamyltransferase (γGT) and AP, and the liver function by bilirubin and albumin. Results Before the treatment, homo-deltaF508 patients (n = 20) had significantly lower cholesterol and vitamin E compared to hetero-deltaF508 (n = 20). Lumacaftor/ivacaftor treatment caused: 1) further reduction of cholesterol; 2) lathosterol reduction, suggesting a normalization of endogenous synthesis; 3) cholestanol and vitamin E increment, indicating an improvement of lipid digestion/absorption. Vitamin E difference (after-before treatment) was positively associated to treatment months. Alkaline phosphatase was also reduced. Conclusions These data suggest an effect of lumacaftor/ivacaftor on cholesterol metabolism and enterohepatic flux in CF patients. However, lumacaftor/ivacaftor does not promote the increase of cholesterol serum concentration that on the contrary declines. Further studies are needed to research the real mechanism causing this reduction.
- Subjects :
- 0301 basic medicine
Pulmonary and Respiratory Medicine
Adult
Male
medicine.medical_specialty
Cystic Fibrosis
Aminopyridines
Cystic Fibrosis Transmembrane Conductance Regulator
Lathosterol
Quinolones
Aminophenols
Intestinal absorption
Ivacaftor
03 medical and health sciences
chemistry.chemical_compound
Young Adult
0302 clinical medicine
Internal medicine
Cholesterol homeostasi
medicine
Humans
Lumacaftor/ivacaftor
Benzodioxoles
Gas chromatography
biology
business.industry
Lumacaftor
medicine.disease
Hypocholesterolemia
Drug Combinations
030104 developmental biology
Endocrinology
Cholesterol
Treatment Outcome
030228 respiratory system
chemistry
Alanine transaminase
Liver
Cystic fibrosi
Pediatrics, Perinatology and Child Health
Mutation
biology.protein
Female
Liver function
business
Pancreatic insufficiency
Lipid digestion
medicine.drug
Subjects
Details
- ISSN :
- 18735010
- Volume :
- 20
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
- Accession number :
- edsair.doi.dedup.....827fc96f5245bb2245e313278b7b9703